Modality
ASO
MOA
BETi
Target
EZH2
Pathway
Checkpoint
BCCT2D
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
Jun 2017
→ Aug 2031
Phase 1Current
NCT07657245
667 pts·T2D
2017-06→2031-08·Not yet recruiting
NCT05644767
1,362 pts·BCC
2019-03→2026-08·Not yet recruiting
2,029 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-205mo awayInterim· BCC
2031-08-035.3y awayInterim· T2D
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Not yet…
P1
Not yet…
Catalysts
Interim
2026-08-20 · 5mo away
BCC
Interim
2031-08-03 · 5.3y away
T2D
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07657245 | Phase 1 | T2D | Not yet recr... | 667 | Safety |
| NCT05644767 | Phase 1 | BCC | Not yet recr... | 1362 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| 369-8021 | Hansoh Pharma | Approved | BTK | |
| COR-9456 | Corcept | Preclinical | TIGIT |